Norwegian version of this page

22.5 million for UiO from the Norwegian Cancer Society

Three of the Faculty of Medicine’s research communities, as well as a research community at the Faculty of Mathematics and Natural Sciences, have received funding amounting to millions of Norwegian kroner from the Norwegian Cancer Society. A total of 11 research communities from Oslo University Hospital and Akershus University Hospital affiliated to the research at UiO have also received funding.

The award of the research funding in the Professor Residence on 28 October. Photo: Eirin Sørensen Røkke, Norwegian Cancer Society

The Norwegian Cancer Society has donated NOK 24.5 million for research at UiO, distributed among four research projects at the Faculty of Medicine and the Faculty of Mathematics and Natural Sciences. The Norwegian Cancer Society allocated a total of NOK 179 to Norwegian research communities.

40 million for research on immunotherapy

A total of NOK 40 million goes to immunotherapy research projects. Anne Lise Ryel, Secretary General of the Norwegian Cancer Society, tells us that she is looking forward to all the exciting, high-quality research projects in this area. This is the cancer therapy of the future, and has relevance across the different diagnoses.

‘It is wonderful that we are able give such a large amount to the best cancer research communities in Norway. We can do this thanks to our ever-generous donors, both large and small, and our members. This is more than just a gift; it is an investment in even better cancer care in the future,’ says Ryel.

When the Norwegian Cancer Society visited UiO on 28 October, the allocation based on the annual open call for funding was made public.

The following were allocated funding at UiO

  • NOK 5 million to Bjarne Bogen, Institute of Clinical Medicine, Faculty of Medicine. Project title: Patient-specific cancer vaccines delivered with targeted DNA.
  • NOK 6 million to Hesso Farhan, Institute of Basic Medical Sciences, Faculty of Medicine. Project title: Spatial Cdc42 signaling at the golgi and the regulation of cancer cell migration and invasion.
  • NOK 7.5 million to Fahri Saatcioglu, Department of Biosciences, Faculty of Mathematics and Natural Sciences. Project title: Androgen action and prostate cancer: Identification of biomarkers and therapeutic targets.
  • NOK 6 million to Kjetil Taskén, Centre for Molecular Medicine Norway (NCCM) at the Faculty of Medicine. Project title: Targeting tumor immune evasion mechanisms mediated by prostaglandin E2, cyclic AMP and regulatory T cells.

Research groups applying via Oslo and Akershus University Hospitals

Several scientists affiliated to research groups at the Faculty of Medicine and the Faculty of Mathematics and Natural Sciences have also been allocated funding through applications via Oslo University Hospital.

  • NOK 5 million went to professor Hilde Nilsen, Head at the Department of Clinical Molecular Biology. Project title: Genome instability and inflammation in early stages of cancer development. The allocation went to Akershus University Hospital.
  • NOK 8 million went to professor Anne Ree at the Institute of Clinical Medicine. Project title: Shaping antitumor immunity in advanced colorectal cancer. The allocation went to Akershus University Hospital.
  • NOK 4.7 million went to Svein Dueland at the Experimental transplantation for cancer research Group (in Norwegian) at the Institute of Clinical Medicine. Project title: Liver transplantation in selected patients with colorectal cancer liver metastases. The allocation went to Oslo University Hospital, Radiumhospitalet.
  • NOK 7.5 million went to Jon Amund Kyte at the Breast cancer research group (in Norwegian) at the Institute of Clinical Medicine. Project title: Immunotherapy with retargeted T cells against solid cancers. The allocation went to Oslo University Hospital, Radiumhospitalet.
  • NOK 8.6 million went to Heidi Lyng at the Gynaecological oncology research group (in Norwegian), Institute of Clinical Medicine. Project title: Molecular biomarkers in radiotherapy of cancer. The allocation went to Oslo University Hospital, Radiumhospitalet.
  • NOK 4.2 million went to professor Eirik Malinen at the Department of Physics, Faculty of Mathematics and Natural Sciences. Project title: Bioradiance. The allocation went to Oslo University Hospital, Radiumhospitalet.
  • NOK 7.5 million to professor Johanna Olweus at the K.G. Jebsen Centre for Cancer Immunotherapy. Project title: Outsourcing cancer-specific immunity to healthy donors. The allocation went to Oslo University Hospital, Radiumhospitalet.
  • NOK 7.75 million to Erlend Bremertun Smeland at CCB – Centre for Cancer Biomedicine, Smeland group - Translational research in malignant lymphoma. Project title: Precision medicine in B-cell lymphoma. The allocation went to Oslo University Hospital, Radiumhospitalet.
  • NOK 7.5 million to professor Harald Stenmark, CCB – Centre for Cancer Biomedicine. Project title: Dysregulated cell division and its implications for cancer. The allocation went to Oslo University Hospital, Radiumhospitalet.
  • NOK 5.95 million to Bjørn Atle Bjørnbeth at the K.G. Jebsen Inflammation Research Centre. Project title: Acetylsalicylic acid as secondary prevention in colorectal cancer (ASAC trial). The allocation went to Oslo University Hospital, Rikshospitalet.
  • NOK 6 million to Magnar Bjørås, Department of Microbiology at the Institute of Clinical Medicine. Project title: Oxidative stress induced DNA base modifications in cancer: Novel biomarkers and drug targets. The allocation went to Oslo University Hospital, Rikshospitalet.

See the full overview of this year’s research funding allocations from the Norwegian Cancer Society (pdf).

By Silje M. Kile Rosseland
Published Nov. 4, 2016 1:59 PM - Last modified Nov. 4, 2016 2:05 PM